NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. ...

PHILADELPHIA, May 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired VIATRIS securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff represent ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the June 3, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by June 3, 2025, to serve as lead plaintiff [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that affected the shipment of eleven products [4]. - Defendants allegedly downplayed the impact of the warning letter, referring to it as a "minor headwind," while failing to disclose critical details about the inspection and remediation efforts [5]. - The misleading statements led investors to purchase Viatris securities at artificially inflated prices, resulting in damages when the true information became public [5].

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS). Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=150521&from=3  CLASS PERIOD: August 8, 2024 to ...

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented the condition of its facilities, stating they were in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In the Q4 2024 results released on February 27, 2025, Viatris disclosed that the failed inspection would lower 2025 revenue by approximately $500 million and earnings from operations by approximately $385 million [5]. - Following this announcement, Viatris's stock price fell about 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=150490&from=4CLASS PERIOD: August 8, 2024 to February ...

NEW YORK, May 28, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viatris Inc. (NASDAQ: VTRS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Viatris caused the company to misrepresent or fail to disclose information concerning the failed inspection of Viatris' Indore, India facility, including, (1) when the inspection occurred, (2) how long the remediation efforts had ...

PHILADELPHIA, May 28, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against VIATRIS INC. ("Viatris" or the "Company") (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Viatris securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff representative ...

Core Viewpoint - A class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors regarding the company's revenue and growth challenges, particularly related to a failed FDA inspection at its Indore facility [3][4]. Group 1: Class Action Details - The class action represents investors who purchased Viatris securities between August 8, 2024, and February 26, 2025, with a deadline of June 3, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and complimentary case evaluations [2]. Group 2: Allegations Against Viatris - The lawsuit claims that Viatris downplayed the seriousness of the failed FDA inspection and its consequences, leading to a false impression of the company's stability [3]. - It is alleged that Viatris underestimated the impact of the FDA inspection failure, which resulted in significant setbacks, including ongoing remediation efforts and disruptions in manufacturing and shipping key products like Lenalidomide [4]. Group 3: Financial Impact - On February 27, 2025, Viatris reported disappointing fourth-quarter and full-year 2024 financial results, along with guidance for fiscal year 2025 that reflected the expected financial effects of the FDA warning letter [5]. - Following this announcement, Viatris' stock price experienced a decline of over 15% [5].

NEW YORK, May 27, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. (NASDAQ: VTRS) between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"), of the important June 3, 2025 lead plaintiff deadline.So what: If you purchased Viatris securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to do next:  ...